 There is little evidence of the therapeutic value of using antidepressants in dementia whatever the indication  A better understanding of the aetiologies underlying neuropsychiatric symptoms in dementia would assist the development of future treatments 
Key points:
 There is little evidence of the therapeutic value of using antidepressants in dementia whatever the indication  A better understanding of the aetiologies underlying neuropsychiatric symptoms in dementia would assist the development of future treatments  Antidepressants have adverse effects when used in those with dementia  Further large scale high quality RCTs are needed to test the role of antidepressants in under-researched areas such as anxiety and agitation in dementia and discontinuation of antidepressants in dementia
INTRODUCTION
Antidepressants are commonly used in dementia, but do they do any good?
Depression is a frequent and important co-morbidity in dementia and antidepressants are often used to treat the syndrome of depression. They are also used to treat other behavioural and psychological symptoms of dementia (BPSD) (Finkel et al., 2000) including agitation, aggression, psychosis and apathy (Burns and Iliffe, 2009 ). There is a need for effective treatment of depression and other BPSD, because of their profound negative impact on individuals with dementia and their caregivers. They complicate patient care , increase the cost of care (Beeri et al., 2002) and result in caregiver burden (Coen et al., 1997) , rapid cognitive decline (Stern et al., 1987) , impairment in activities of daily living (ADL) Mok et al., 2004 ) and poorer quality of life (QoL) (González-Salvador et al., 2000) . Each of these has a profound negative impact on both the person with dementia and carers, so treatment is a clinical priority. Systematic reviews of the literature have generally found little or equivocal evidence for the effectiveness of antidepressants in the treatment of depression in dementia (Bains et al., 2002; Nelson and Devanand, 2011) or BPSD (Sink et al., 2005) .
Despite this, 25-42% of all those with dementia may be prescribed antidepressants (Pitkala et al., 2004; Snowdon et al., 2011) . Due to their widespread use in the absence of definitive evidence of their effects and side effects in populations with dementia, it is important to establish their efficacy and tolerability in dementia. No review to date has taken account of the multiple potential targets for antidepressants in dementia. In this narrative review we seek to present RCT data to enable a balanced appraisal of the use of antidepressants in dementia across indications.
REVIEW
This paper is a narrative review. In comparison to a systematic review, a narrative review is less formal and systematic and subjective methods are used to interpret information, which is then summarised subjectively and narratively (Klassen et al., 1998) . We chose this format rather than that of a systematic review because of the nature of the data available and the breadth of the question posed. Formal systematic review methodology is not well suited to answering multiple questions in a broad literature of variable quality.
We performed a literature search using the PubMed database for peer-reviewed publications available on 9 December 2015, without language restrictions. The following search terms were used; 'depression', 'dementia', 'Alzheimer's disease', 'antidepressant', 'SSRIs', 'anxiety', 'agitation', 'aggression', 'psychosis', 'apathy', 'behavioural and psychological symptoms', 'BPSD' and 'CSDD' (Cornell Scale for Depression in Dementia). Results were filtered to include only RCTs. For inclusion, RCTs were required to have an antidepressant treatment arm being administered to a dementia population. Trials were excluded if the sample population were cognitively healthy or had mild cognitive impairment (MCI). In trials with both dementia and non-dementia participants, outcomes for the dementia subgroup needed to be reported separately. There was no exclusion criteria based on age, gender or dementia subtype. Trials were excluded if they did not use validated measures of the following outcomes: depression, agitation/aggression, anxiety, apathy, psychosis, cognitive status, functional status, carer burden, QoL, clinical severity and global BPSD. Systematic reviews and meta-analyses were sought through PubMed and The Cochrane Library to provide guidance on the narrative and to identify additional studies that may have been missed in the initial search. Titles and abstracts were independently screened by two authors (NF and LM) before fulltexts were obtained and screened.
Following exclusions, the search identified thirty-four RCTs; two additional RCTs were identified after reading relevant literature (Finkel et al., 2004; Gaber et al., 2001) . A summary of outcome measures of identified RCTs were extracted (Table   1 ). Information on sample population, intervention type and results associated with antidepressant treatment and how they compared to a placebo group or comparator, were also extracted ( Table 2 ). All data were extracted by a single author (NF) and independently verified by a second author (LM). In addition to the RCTs, we identified three Cochrane reviews (Bains et al., 2002; Martinón-Torres et al., 2004; Seitz et al., 2011) and six systematic reviews (Henry et al., 2011; Leong, 2014; Nelson and Devanand, 2011; Sepehry et al., 2012; Sink et al., 2005; Thompson et al., 2007) .
Risk of bias was subsequently assessed using The Cochrane Collaboration's tool for assessing risk of bias (Higgins et al., 2011) by NF and independently confirmed by SB. The tool was used as means to describe the risk of bias and it was not used a means to exclude any studies. The majority of studies were deemed as having 'unclear' or 'low' risk of bias across all elements. Many of the unclear judgements were as a result of poor reporting. For example, the majority of studies reported as "double-blind" did not describe the steps they took to ensure this and whether it was successfully maintained. Nine studies were deemed to have at least 1 element of high risk of bias. One study (Moretti et al., 2002) had multiple elements judged as having a high risk of bias; this was largely due to the fact it was not double-blinded.
Three studies were judged to have low risk of bias across all elements: HTA-SADD ), DIADS-II (Drye et al., 2011 Martin et al., 2006; Rosenberg et al., 2010; Weintraub et al., 2010) , and CitAD (Peters et al., 2015; Porsteinsson et al., 2014) (Table 3) .
Antidepressants for depression in dementia
Apart from a few exceptions (e.g. Choe et al., 2015; Pollock et al., 2002) , it is clear that most individuals recruited into trials of selective serotonin reuptake inhibitor (SSRI) antidepressants or serotonin-noradrenaline reuptake inhibitors (SNRIs) have experienced reduced depressive symptoms from baseline to endpoint (Banerjee et al., 2011; Bergh et al., 2012; Karlsson et al., 2000; Katona et al., 1998; Lyketsos et al., 2003 Lyketsos et al., , 2000b Magai et al., 2000; Moretti et al., 2002; Mowla et al., 2007; Nyth et al., 1992; Nyth and Gottfries, 1990; Petracca et al., 2001; Taragano et al., 1997; Nyth and Gottfries, 1990) . However, the same magnitude of change is seen in the placebo group so these decreases in depression are not attributable to the antidepressants. Two trials found a significant improvement above that of placebo (Lebert et al., 2004; Lyketsos et al., 2003) ; they were both small in sample size and Lebert and colleagues did not use a measure of depression validated in dementia (Lebert et al., 2004 ).
The quality of the studies available is an important consideration. The Cochrane review Antidepressants for treating depression in dementia (Bains et al., 2002) identified only four studies which reported sufficiently detailed results to enter into a meta-analysis, with a total of 137 subjects. The review concluded that the evidence for clinical effectiveness of antidepressants for depression in dementia was equivocal and weak and that the small possibility of positive effect was driven by the highly positive DIADS study of sertraline (Lyketsos et al., 2003) . Since that review, the much larger DIADS-II study (Drye et al., 2011; Rosenberg et al., 2010; Weintraub et al., 2010) has yielded robust data demonstrating that sertraline is not superior to placebo in the treatment of depression in dementia. They found no benefit of sertraline over placebo at 12 or 24 weeks. When these data are added to those from the HTA-SADD Trial (Banerjee et al., , 2011 , which found no superiority of sertraline over placebo in a larger sample (n=326) at 13 and 39 weeks of treatment, the evidence base suggests that SSRI antidepressants do not appear to work as a treatment for depression in dementia.
There are a number of older and generally smaller trials which have investigated tricyclic antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs) (Petracca et al., 1996; Reifler et al., 1989; Roth et al., 1996; Teri et al., 1991) . The quality of these studies reflects their age; the outcome measures used are not developed or validated for use in dementia; these studies often do not meet the quality thresholds needed for inclusion in modern systematic reviews. Two RCTs explored the effects of imipramine on depression in dementia and found no benefit over placebo (Teri et al., 1991; Reifler et al., 1989) . In a very small double-blind cross-over RCT of clomipramine, participants receiving the treatment significantly improved in Hamilton Depression Rating Scale (HDRS) score and remission rate, compared to placebo (Petracca et al., 1996) . Similarly, Roth and colleagues found the MAOI, moclobemide had some effect in improving HDRS scores in a mixed group of cognitive impairment in comparison to placebo (Roth et al., 1996) . Quality issues in the design of these studies as well as the appreciable side effects of these classes of antidepressants, mean that their clinical utility remains unproven.
Few trials have investigated the effects of newer, non-SSRI antidepressants on depression in dementia. The HTA-SADD trial, found that treatment with mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), was no better than treatment with placebo over 13 and 39 weeks (Banerjee et al., , 2011 .
Fuchs and colleagues reported that the tetracyclic antidepressant maprotiline was significantly better at improving depression scores compared to placebo on the Geriatric Depression Scale (GDS; p=0.09) (Fuchs et al., 1993) . Caution should be taken interpreting this on methodological grounds; statistical significance was set at 10% rather than the usual 5% level and the GDS has limitations in populations with dementia (Burke et al., 1989; Kørner et al., 2006) .
A balanced appraisal of the evidence suggests, taking into account the methodological limitation of older studies, that the antidepressants tested to date show no convincing advantage over placebo for the treatment of depression in dementia.
Antidepressants for anxiety in dementia
Despite anxiety being common in dementia (Badrakalimuthu and Tarbuck, 2012) and previous recommendations to use antidepressants in its treatment (Sink et al., 2005) , few RCTs have investigated the effects of antidepressants on anxiety in dementia. In four trials, treatment had no significant effect on anxiety score over placebo (Lebert et al., 2004; Teranishi et al., 2013; Nyth et al., 1992; Nyth and Gottfries, 1990) . In all four trials anxiety was only measured using subscale of a broader assessment tool.
One other RCT used a specific and validated measure of anxiety (Petracca et al., 2001 ) but again found no significant improvement in anxiety scores compared with placebo.
What is striking is the lack of large well-designed trials designed to generate a definitive appraisal of the clinical effectiveness of antidepressants for anxiety in dementia. Despite its reported impact on those with dementia and their carers, the management of anxiety in dementia has attracted little attention in terms of research and/or funding. This area would benefit from further research.
Antidepressants for agitation in dementia
Agitation, defined as inappropriate verbal, vocal or motor activity, which is not an expression of unmet need, and which encompasses physical and verbal aggression (Cohen-Mansfield and Billig, 1986) , is particularly problematic in dementia. It can affect 50% of people with AD over a month (Okura et al., 2010) and appears to persist (Ryu et al., 2005) . It is associated with deteriorating relationships with family and professional carers, institutionalisation, increased costs of care, carer burden, carer burnout and decreased QoL (Okura et al., 2010; Ryu et al., 2005; Wetzels et al., 2010) . As such, it is a legitimate target for intervention (Banerjee, 2009 ).
Antipsychotic medication, the current mainstay of drug treatment for agitation and aggression in dementia, has only a limited positive effect in treating symptoms and can cause significant harm to people with dementia (Banerjee, 2009; Gill et al., 2007) .
Despite much research, no other drugs have a proven positive role in the treatment of agitation, but antidepressants have been considered as a possible alternative to antipsychotics (Tariot et al., 1998 (Tariot et al., , 1995 . Sulzter and colleagues compared the efficacy of trazodone to haloperidol, in the treatment of agitation in dementia (Sultzer et al., 2001 (Sultzer et al., , 1997 . Results indicated that they were equally effective overall. Similar findings have been reported comparing sertraline to haloperidol treatment (Gaber et al., 2001) . However, the small sample sizes (n=28 and 23 respectively) and lack of a placebo group in both trials, limit the interpretation of these findings. They are not likely to have been powered appropriately to make valid inferences of equivalence of effect.
Two studies have reported that antidepressants reduce agitation compared to placebo in dementia Porsteinsson et al., 2014) , however much of the literature has found no significant treatment effect (Auchus and Bissey-Black, 1997; Finkel et al., 2004; Lanctôt et al., 2002; Magai et al., 2000; Pollock et al., 2007; Sultzer et al., 2001 Sultzer et al., , 1997 Teranishi et al., 2013; Teri et al., 2000) . One potential limitation of the majority of these studies (all but Auchus and Bissey-Black, 1997; Porsteinsson et al., 2014; Sultzer et al., 2001 Sultzer et al., , 1997 , is that they treated agitation as a continuous variable and did not require participants to have clinically significant agitation on enrolment.
The best trial in this area is the large (n=186) well-designed CitAD trial (Peters et al., 2015; Porsteinsson et al., 2014) . In this 9 week RCT comparing citalopram with placebo, all participants had probable AD and clinically significant agitation. The trial found that citalopram led to a reduction in agitation, measured by the agitation subscale of the Neurobehavioral Rating Scale (−0.93 (95% CI, −1.80 to −0.06), p=0.04). CitAD provides evidence that 30mg citalopram daily has a positive effect on agitation in dementia. It also confirms safety concerns for citalopram (US FDA, 2012) . The adverse cardiac effects identified in the trial, and to a lesser extent the cognitive impairment observed, is likely to limit use in clinical practice (National Institute for Health and Care Excellence, 2014). The CitAD trial is however encouraging, this evidence of antidepressant efficacy supports the need for further research and is a proof of the concept that antidepressants as a class of drugs may have a role in the management of agitation in dementia.
Antidepressants for psychosis in dementia
Psychotic symptoms (hallucinations and delusions) may affect 60% of those with dementia (Ballard et al., 1995) . Antipsychotic medication is traditionally used to treat psychotic symptoms in dementia, in line with treatment practice in those without cognitive impairment. However, as noted above antipsychotics are associated adverse events in dementia including an increase in mortality (Gill et al., 2007; Schneider et al., 2005) . In light of this, there is a desire to test alternate treatments such as antidepressants. In a recent RCT (Teranishi et al., 2013) , 82 patients with dementia and neuropsychiatric symptoms were randomly assigned to receive risperidone, fluvoxamine or yokukansa (a traditional Japanese herbal remedy) for 8 weeks. Those receiving fluvoxamine had a significant improvement in delusion but not hallucination scores over the trial, but there were no between-group effects on either delusion or hallucination scores and no placebo with which to compare the effects.
Other trials have reported similar findings (Bergh et al., 2012; Lebert et al., 2004; Pollock et al., 2007 Pollock et al., , 2002 Sultzer et al., 2001 ) but these are largely secondary analyses of RCTs designed to investigate other primary hypotheses. So participants were generally not selected on the basis of having psychosis in dementia, the measures chosen often lack in detail and the trials do not include a placebo group (all but Pollock et al., 2002 ). An exception is the small study by Levkovitz and colleagues where 20 participants with AD and psychotic symptoms were randomly assigned perphenazine with either fluvoxamine or placebo in a 6 week cross-over RCT (Levkovitz et al., 2001) . Those receiving adjunctive fluvoxamine significantly improved scores on the Brief Psychiatric Rating Scale (BPRS) compared to placebo.
At present, the evidence base for the value of antidepressant use for psychosis in dementia is weak with little suggestion of positive effect. There would be value in further research in this area.
Antidepressants for apathy in dementia
Apathy is a core element of depression and so separating it from depression is problematic. However, there have been observations of apathy without apparent depression in dementia, so apathy has been proposed as a behavioural syndrome characterized by a decrease in interest, motivation, or initiation of action (van Reekum et al., 2005) . Apathy so defined is a common neuropsychiatric syndrome in AD, with a prevalence of 92% in severe AD (Mega et al., 1996) . There is little evidence to support the notion that antidepressants might have a specific effect on apathy in dementia. Bergh and colleagues discontinued SSRI medication for 25 weeks in 63 patients with AD, VaD or mixed dementia with neuropsychiatric symptoms (Bergh et al., 2012) . Apathy scores were found not to differ significantly between those that discontinued or continued SSRI treatment. Fluvoxamine (Teranishi et al., 2013) , trazodone (Lebert et al., 2004) , and citalopram have also been reported to have no effect on apathy scores.
No trial to date has defined participants by clinical level of apathy at baseline. There is little evidence for a role of antidepressants in the specific treatment of apathy in dementia.
Antidepressants and carer burden in dementia
BPSD is associated with carer burden (Burns and Rabins, 2000; Coen et al., 1997) .
Few trials have explored the impact of antidepressants given to the person with dementia on carer burden; in most no significant treatment effects were observed (Auchus and Bissey-Black, 1997; Banerjee et al., 2013 Banerjee et al., , 2011 Finkel et al., 2004; Lyketsos et al., 2003; Teri et al., 2000) . Two studies reported that antidepressants had a positive effect on carer burden (Moretti et al., 2002; Porsteinsson et al., 2014) both also showed the antidepressant improved BPSD, suggesting a pathway to relief of carer burden via the relief of BPSD in the person with dementia. In terms of objective burden, HTA-SADD found those randomised to mirtazapine required half the unpaid carer time, compared with those receiving placebo or sertraline . It is possible this effect was mediated via the putative ability of mirtazapine to ameliorate sleep disturbance. Improvements in sleep could potentially release carer time directly and address an important source of carer distress. In this way an antidepressant might have a general effect, beneficial for both the patient and the carer, without exerting a specific antidepressant effect.
Antidepressants and activities of daily living in dementia
Function in terms of ADL is a common secondary outcome measure when investigating the effects of antidepressants in dementia. All but two studies suggest that antidepressants do not further impair ADL in dementia (Banerjee et al., , 2011 Bergh et al., 2012; Finkel et al., 2004; Lyketsos et al., 2003 Lyketsos et al., , 2000a Moretti et al., 2002; Petracca et al., 1996 Petracca et al., , 2001 Porsteinsson et al., 2014; Reifler et al., 1989; Teranishi et al., 2013; Weintraub et al., 2010) . One reported a positive effect (Mowla et al., 2007) and one a negative effect (Teri et al., 2000) . On balance there is no evidence at present to suggest that antidepressants have a positive or negative effect on ADLs in dementia.
Antidepressants and cognition in dementia
In terms of improving cognition in people with dementia, there is little evidence to suggest that antidepressants have any effect. The DIADS, DIADS-II, and HTA-SADD trials of depression in dementia, all showed no effect on cognition in those randomised to sertraline or mirtazapine treatments compared with placebo treatment , Lyketsos et al., 2003 , 2000a Munro et al., 2004; Rosenberg et al., 2010) . This has been echoed in other studies investigating the effects of other antidepressants (Choe et al., 2015; Levkovitz et al., 2001; Olafsson et al., 1992; Teri et al., 1991; Weintraub et al., 2010) . There is some evidence to suggest that cognitive function (Petracca et al., 1996; Porsteinsson et al., 2014; Teri et al., 2000) or specific cognitive measures (Deakin et al., 2004; Reifler et al., 1989) may be negatively impacted by some antidepressants. However, a few trials also exist which have reported a significant improvement in cognitive performance following treatment compared to placebo (Mowla et al., 2007; Nyth et al., 1992; Roth et al., 1996) . It is important to note however, that bar a few exceptions (e.g. Deakin et al., 2004; Mowla et al., 2007; Munro et al., 2012 Munro et al., , 2004 Olafsson et al., 1992; Teri et al., 1991) , most RCTs do not use a comprehensive cognitive battery. Instead many RCTs have explored cognition using a single global cognitive measure; typically the Mini Mental State Examination (MMSE). Cognition is a secondary outcome in these studies and the MMSE is used to primarily to describe the sample rather than as a discriminative outcome measure.
Adverse events of antidepressants in dementia
Whilst the effects of antidepressants on BPSD and other secondary outcomes in dementia are equivocal at best, it is clear that antidepressants cause a set of adverse events. Commonly occurring adverse events include: anxiety and nervousness (Auchus and Bissey-Black, 1997; Finkel et al., 2004) , tremors (Auchus and Bissey-Black, 1997; Lanctôt et al., 2002) , anorexia (Finkel et al., 2004; Moretti et al., 2002; Porsteinsson et al., 2014; Teranishi et al., 2013) and falls (Lanctôt et al., 2002; Teranishi et al., 2013 ). In addition, the level of adverse event reporting is high in absolute terms. HTA-SADD reported 43% of participants receiving sertraline and 41% receiving mirtazapine showed adverse reactions compared to 26% on placebo (Banerjee et al., 2011) . Porsteinsson and colleagues found 96% of participants taking citalopram had an adverse event , with diarrhoea, anorexia, fever, impaired cognition and QT interval prolongation significantly greater in the citalopram group compared to placebo. Despite the levels of adverse events being high, study discontinuation appears relatively low and not higher in those receiving antidepressant treatment compared to placebo (9.0% vs 6.0% respectively) (Nelson and Devanand, 2011) .
DISCUSSION
The findings from this narrative review of the literature suggest that despite being very commonly used, the evidence for antidepressants having a positive role in dementia is weak. A consistent finding is that any change observed in outcomes is also seen in the placebo group. There is no good evidence that antidepressants are effective in improving depression, ADL, cognition or carer burden. There are however harms that are attributable to the use of antidepressants, which are common and in some cases serious Porsteinsson et al., 2014) . In view of these adverse effects, the lack of evidence for positive effects, and how commonly they are prescribed, further trials investigating the effect of withdrawing antidepressants in dementia from those where they have been used for long periods would be of value.
To be clinically useful, studies need well defined and relevant sample populations.
From this review it is apparent that many past trials have explored the effects of antidepressants on a large battery of secondary outcomes, in trials designed to test other hypotheses. However, there has been a positive move to greater methodological precision in recent trials of antidepressants in dementia (Banerjee et al., 2011; Porsteinsson et al., 2014; Rosenberg et al., 2010) . This includes larger sample sizes with greater power, more generalisable study populations, correct use of blinding and placebo groups, greater specificity in the population chosen for study (e.g. depression in dementia, agitation in dementia) and clarity in the primary outcomes, secondary outcomes and the measures chosen to assess them. The data from such trials are much more likely to be of direct clinical relevance and to generate definitive results.
It is important to note that there are several limitations of this review. First, whilst every attempt was made to identify the relevant literature by having broad search terms and searching citations, there is the possibility that some trials may have been missed. Second, this review did not exclude any study on the basis of their study quality, this may lead the significance of some findings to be over reported. We have attempted to account for this by putting a greater emphasis on larger studies, which have been judged to have a lower risk of bias.
The lack of efficacy in treating BPSD with antidepressants is perhaps understandable when we consider that we are trying to treat a complex phenomenon with a simple intervention. Antidepressants that work in cognitively normal groups of older people with depression do not seem to work in those with depression in dementia. In part, this is likely to be due to greater heterogeneity in depression in dementia compared to depression without dementia. Dementia introduces multiple extra dimensions of complexity. Depression in dementia is likely to include at least three distinct groups:
(i) A group where depression is situationally determined as a reaction to the impacts of dementia and may respond to problem solving and support. This is akin to 'reactive' depression and might respond to clinical support provided by dementia diagnostic and care services rather than to antidepressants. This would explain some of the positive change observed in those receiving placebo (but also usual care) in studies including DIADS-II and HTA-SADD.
(ii) A homophenotypic group where the syndrome looks like depression but may have a different biological basis that is a function of the neurodegeneration of the dementia process. This group is likely to have a different neurochemistry compared with depression in those without dementia.
This might explain the different (poorer) response to antidepressant treatment in those with depression in dementia.
(iii) A group who carry a past history of depression (given it is a recurrent disorder) into dementia or who develop a 'true' episode of major depressive disorder in dementia. In these cases antidepressant response may be similar to that in depression without dementia, but there might also be attenuation in treatment response due to the neurodegeneration and neurochemical changes that are part of dementia.
There are data to support such heterogeneity. Zarb reported cognitively impaired patients with higher verbal intellectual functioning were more likely to be depressed (Zarb, 1996) . This might be due to greater embarrassment and sadness at their memory decline or a greater awareness of their impairment. Conversely, denial of memory deficits has been found to be negatively associated with depression (Sevush and Leve, 1993) . People with depression in dementia have neuropathological differences compared to patients without depression including degeneration of the locus coeruleus and substantia nigra (Zubenko and Moossy, 1988) or the locus coeruleus and the central superior nucleus (Zweig et al., 1988) .
Degeneration of these nuclei are associated with deficits in noradrenaline and serotonin, both of which are related to mood (Zubenko et al., 1990; Zweig et al., 1988) .
Research that seeks to develop treatments for AD and other dementias is increasingly aware of the complexity of these disorders, of the multiple aetiologies that may lead to these syndromes, and which may determine differential treatment response. These findings underline that this complexity is just as likely to be active in the BPSD that drive QoL in dementia, as in dementia itself. Current clinical practice in the use of antidepressants in dementia is more based in an altruistic desire to do something positive about BPSD whilst trying to avoid the harms that come from other drugs like antipsychotics, than it is based upon evidence.
We need better treatments for BPSD. There are intriguing signals in the literature (such as the halving of carer time seen with mirtazapine in HTA-SADD and the positive effects on agitation in CitAD) that antidepressants may have a valuable role in their management. We need to continue the programme of large good quality placebo-controlled RCTs following up leads from the literature to generate the evidence needed for us to be able to treat BPSD effectively and safely, maximising quality of life for those with dementia and their carers. 
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